Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $2.2 million as the latest value for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) fell 6.55% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Feb 2026, down 11.19% year-over-year, with the annual reading at $8.7 million for FY2025, 6.63% down from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 was $2.2 million at Nurix Therapeutics, up from $2.1 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.5 million in Q4 2024, with the low at $991000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.9 million, with a median of $2.0 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 116.67% in 2022, then fell 18.4% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $1.6 million in 2022, then grew by 23.18% to $1.9 million in 2023, then soared by 31.8% to $2.5 million in 2024, then fell by 18.4% to $2.1 million in 2025, then grew by 5.58% to $2.2 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.2 million, $2.1 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.